Bonkers Bargain: further validation of AI credentials
This small medical imaging advanced analytics company delivering insights in neuroscience has loads of potential and continues to look cracking value at current levels. Our in-depth commentary here highlights its appeal in a sector which is predicted to grow significantly. The order book offers plenty of visibility and this fascinating business is certainly worth a close look. Encouraging results from a drug being developed for Alzheimers disease is positive, while an equity raise has strengthened the balance sheet. The recent validation its AI-driven platform bodes well. It's certainly not our usual type of Bonkers Bargain, but exciting nonetheless!
IXICO (LON:IXI) is an Artificial Intelligence (‘AI’) data analytics company delivering intelligent insights in neuroscience. Its purpose is to advance medicine and human health in neuroscience by converting raw clinical trial data into clinically meaningful information.
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.
REGISTER FREE
More on IXICO
Bonkers Bargain: further validation of AI credentials
This small medical imaging advanced analytics company delivering insights in neuroscience has loads of potential and…
Important partners | Attractive valuation | Bonkers Bargains
News covered here includes our assessment of results from one of AIM’s insolvency specialists. We consider…
